论文部分内容阅读
用酶联免疫吸附测定法测定５８例脑肿瘤患者及１２例正常人的血清及脑脊液中髓鞘碱性蛋白（ＭＢＰ）含量。发现血清ＭＢＰ与脑脊液ＭＢＰ呈正相关；恶性脑肿瘤患者血清及脑脊液ＭＢＰ含量高于良性肿瘤、高分化胶质瘤患者及正常人；颅内压增高可促进ＭＢＰ释放；肿瘤体积较大、瘤周水肿及脑组织明显移位可使血清及脑脊液ＭＢＰ增高。提示测定血清及脑脊液中ＭＢＰ有助于鉴别脑部良恶性肿瘤及估计神经系统受损程度。
Enzyme-linked immunosorbent assay was used to determine the levels of MBP in serum and cerebrospinal fluid of 58 patients with brain tumors and 12 normal controls. It was found that serum MBP was positively correlated with cerebrospinal fluid MBP; MBP levels in serum and cerebrospinal fluid in patients with malignant brain tumors were higher than those in benign tumors, well-differentiated glioma patients, and normal people; increased intracranial pressure could promote the release of MBP; tumor size was large and peritumoral edema And significant shifts in brain tissue can increase serum and cerebrospinal fluid MBP. It is suggested that the determination of MBP in serum and cerebrospinal fluid may help identify benign and malignant tumors in the brain and estimate the extent of nervous system damage.